<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020678</url>
  </required_header>
  <id_info>
    <org_study_id>NKX019-101</org_study_id>
    <nct_id>NCT05020678</nct_id>
  </id_info>
  <brief_title>NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers</brief_title>
  <official_title>A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nkarta Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nkarta Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and&#xD;
      tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting&#xD;
      CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic&#xD;
      leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-finding study of NKX019 and will be conducted in 2 parts:&#xD;
&#xD;
      Part 1: dose finding utilizing a &quot;3+3&quot; enrollment schema. Part 2: dose expansion to further&#xD;
      evaluate safety and tolerability, cellular kinetics, pharmacodynamics and anti-tumor response&#xD;
      in expansion cohorts of patients with large B cell lymphoma (LBCL), mantle cell lymphoma&#xD;
      (MCL), indolent lymphoma (IL), Waldenström macroglobulinemia (WM), CLL/ small lymphocytic&#xD;
      lymphoma (SLL), and B-ALL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Anticipated">July 2038</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>30 days after last dose of NKX019</time_frame>
    <description>Incidence, nature, and severity of treatment related adverse events will be evaluated. An adverse event is any unfavorable and unintended sign including clinically significant abnormal laboratory findings, symptom or disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects experiencing dose-limiting toxicities of NKX019</measure>
    <time_frame>28 days from first dose of NKX019</time_frame>
    <description>DLTs are defined as adverse events attributable to NKX019 treatment that occur during Cycle 1 and meet protocol-specified criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of NKX019 half-life</measure>
    <time_frame>Time Frame: 28 days from first dose of NKX019</time_frame>
    <description>Time required for 50% reduction from maximum amount of circulating NKX019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NKX019 duration of persistence</measure>
    <time_frame>Followed up to 2 years after last dose of NKX019</time_frame>
    <description>Testing NKX019 in peripheral blood every 3 months after dosing to determine persistence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of host immune response against NKX019</measure>
    <time_frame>Followed up to 2 years after last dose of NKX019</time_frame>
    <description>Serum samples will be measured for antibodies against NKX019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate to NKX019</measure>
    <time_frame>Primary assessment: 28 days after first dose of NKX019 followed up to 2 years after last dose of NKX019</time_frame>
    <description>Percentage of subjects with complete and partial response. Response to treatment will be assessed based on: Lugano classification with LYRIC refinement for subjects with NHL (except CLL/SLL and WM); 2018 iwCLL guidelines for subjects with CLL/SLL; Version 1.2020 NCCN for subjects with B-ALL; consensus criteria from the 6th International Workshop on Waldenström Macroglobulinemia for subjects with WM.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Large B-cell Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Indolent Lymphoma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Aggressive Lymphoma</condition>
  <condition>Large-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>NKX019 - CAR NK cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 weekly doses of NKX019 on Day 0, 7, and 14 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NKX019</intervention_name>
    <description>NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10^8 NK cells (2 × 10^6/kg for patients &lt; 50 kg) administered as 3 weekly doses. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.</description>
    <arm_group_label>NKX019 - CAR NK cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
        ECOG performance status ≤1&#xD;
&#xD;
        • Disease Related:&#xD;
&#xD;
          -  Have a histologically or cytologically confirmed diagnosis of r/r B cell NHL or CLL or&#xD;
             B-ALL as defined by WHO 2016 classification&#xD;
&#xD;
          -  Subjects who received prior CD19-directed therapy must have disease that remains CD19+&#xD;
&#xD;
          -  Have measurable disease&#xD;
&#xD;
          -  Have received ≥2 lines of therapy except subjects with MCL and WM, who must have&#xD;
             received at least 1 prior line of therapy&#xD;
&#xD;
          -  Have received a combination of an anti CD20 monoclonal antibody and cytotoxic&#xD;
             chemotherapy for subjects with NHL&#xD;
&#xD;
          -  Received:&#xD;
&#xD;
               -  BTKi for subjects with MCL, CLL/SLL, WM, and other indications where a BTKi is&#xD;
                  approved&#xD;
&#xD;
               -  Venetoclax for subjects with CLL/SLL&#xD;
&#xD;
               -  Tyrosine kinase inhibitor for subjects with Philadelphia chromosome (Ph+) B-ALL&#xD;
&#xD;
          -  Not responded or relapsed within 12 months of completion of their prior line of&#xD;
             therapy, with the exception of a newly diagnosed Richter's transformation of CLL/SLL&#xD;
             or other transformation of an indolent lymphoma, including from WM&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  White blood cell count of ≤20 × 109/L&#xD;
&#xD;
          -  Platelet count ≥30,000/uL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Disease related:&#xD;
&#xD;
          -  Burkitt Lymphoma, primary CNS lymphoma, Richter's transformation to Hodgkin lymphoma&#xD;
&#xD;
          -  Subjects with WM who underwent plasmapheresis &lt;35 days prior to the first dose of&#xD;
             NKX019&#xD;
&#xD;
          -  Subjects with NHL with any evidence of active CNS malignancy&#xD;
&#xD;
          -  Subjects with B-ALL who have extramedullary disease (EMD)&#xD;
&#xD;
          -  Subjects with any prior cellular therapy except subjects enrolling in selected LBCL&#xD;
             expansion cohort who must have received prior CD19 directed CAR T therapy, recent HCT,&#xD;
             or complications from HCT&#xD;
&#xD;
          -  Recent use of any cancer-directed therapy within protocol specified window prior to&#xD;
             the first dose of NKX019&#xD;
&#xD;
          -  Residual toxicities ≥Grade 2 due to prior therapy&#xD;
&#xD;
          -  Other comorbid conditions and concomitant medications prohibited as per study protocol&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Shook, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nkarta Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Shook, MD</last_name>
    <phone>+1 415-651-5080</phone>
    <email>medmonitor@nkartatx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beth Martello</last_name>
    <phone>+1 415-651-5060</phone>
    <email>clinops@nkartatx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter McSweeney, MD</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Peter McSweeney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Hill, MD PhD</last_name>
      <phone>216-445-9451</phone>
      <email>hillb2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Brian Hill, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Christophersen</last_name>
      <phone>+61 2 9355 5702</phone>
      <email>louise.christophersen@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Nada Hamad, MBSS BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Woman's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen W Kennedy, MBBS FRACP</last_name>
      <phone>+61 07 3646 7962</phone>
      <email>glen.kennedy@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Glen Kennedy, MBSS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parkville Cancer Clinical Trials Unit</last_name>
      <phone>+61 3 8559 7456</phone>
      <email>clinicaltrials.enquiries@petermac.org</email>
    </contact>
    <investigator>
      <last_name>Michael Dickinson, MBSS DMedSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19</keyword>
  <keyword>CAR</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Natural killer</keyword>
  <keyword>ACR</keyword>
  <keyword>NKX019</keyword>
  <keyword>IL15</keyword>
  <keyword>Interleukin 15</keyword>
  <keyword>NK cell</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Adoptive cell therapy</keyword>
  <keyword>r/r NHL</keyword>
  <keyword>r/r B-ALL</keyword>
  <keyword>r/r MCL</keyword>
  <keyword>r/r IL</keyword>
  <keyword>r/r WM</keyword>
  <keyword>r/r CLL</keyword>
  <keyword>r/r SLL</keyword>
  <keyword>Aggressive lymphoma</keyword>
  <keyword>Indolent lymphoma</keyword>
  <keyword>LCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

